March 27, 2019

Resolution Liquid Biopsy Assay Detects More Actionable Oncogenic Fusions with Higher Allele Frequency than Guardant360

Results of retrospective NSCLC comparison study to be presented at upcoming AACR Annual Meeting

Resolution Bioscience, Inc. today announced that scientists from Dana-Farber Cancer Institute will be presenting the results of a liquid biopsy comparison study between Resolution’s ctDx-Lung assay and Guardant Health’s Guardant360® at the American Association for Cancer Research (AACR) Annual Meeting on March 29-April 3, 2019.

The comparison study highlights detection challenges of complex mutations such as gene fusions, as well as the need for platform cross-comparisons to realize the potential of liquid biopsy and increase access to personalized cancer care. A cohort of 169 non-small cell lung cancer (NSCLC) patients with Guardant360 results were screened for gene fusions. The team of scientists at Dana-Farber used a soon-to-be-released ctDx-Lung kit to analyze 16 cases that had a rearrangement in their tumor, along with additional banked plasma. All personnel involved in sample analysis were blinded to tumor genotype and Guardant360 results. The team found that the Resolution ctDx-Lung assay identified more actionable gene fusion mutations with higher allele frequencies than the Guardant360 test. The results further demonstrate the potential of the ctDx-Lung kit for patients with advanced NSCLC.

Attendees interested in the presentation “Building an effective concordance study: Plasma Next Generation Sequencing (NGS) for oncogenic fusion detection in non-small cell lung carcinoma (NSCLC)” by Cloud P. Paweletz, PhD, of the Belfer at Dana-Farber Cancer Institute can reference abstract 1374/13. The study will be presented on April 1, 2019 between 8 AM-12 PM in Section 19 of the Georgia World Congress Center Exhibit Hall.

About Resolution ctDx-Lung™
ctDx-Lung is built on Resolution’s patented cell-free DNA NGS analysis platform. The liquid biopsy assay captures and analyzes circulating tumor DNA (ctDNA) for driver mutations in 20 genes associated with NSCLC using Resolution’s proprietary targeted capture NGS chemistry and cloud-based bioinformatics.

About Resolution Bioscience
Resolution Bioscience is a profitable, privately held company dedicated to developing a highly sensitive, non-invasive liquid biopsy platform that improves cancer diagnostics and monitoring for patients around the world. The company has developed and patented core technology for circulating cell-free DNA NGS analysis and was the first to demonstrate identification of all four major types of mutations in a blinded, clinical study. The company is based in Kirkland, WA. For more information, visit

Resolution Bioscience, the Resolution Bioscience logo, and ctDx-Lung are trademarks of Resolution Bioscience, Inc. All other brands may be trademarks of their respective holders.